Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
19.74 USD | +4.28% | -4.91% | -15.46% |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 1.37B 114B |
---|---|---|---|---|---|
Net income 2024 * | -233M -19.44B | Net income 2025 * | -274M -22.86B | EV / Sales 2024 * | - |
Net cash position 2024 * | 388M 32.33B | Net cash position 2025 * | 282M 23.53B | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-5.01
x | P/E ratio 2025 * |
-4.4
x | Employees | 56 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.16% |
Latest transcript on Akero Therapeutics, Inc.
1 day | +4.28% | ||
1 week | -4.91% | ||
Current month | -21.85% | ||
1 month | -21.85% | ||
3 months | -10.76% | ||
6 months | +73.46% | ||
Current year | -15.46% |
Managers | Title | Age | Since |
---|---|---|---|
Jonathan Young
FOU | Founder | 54 | 01/17/01 |
Timothy Rolph
FOU | Founder | 70 | 01/17/01 |
Andrew Cheng
CEO | Chief Executive Officer | 57 | 01/18/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Seth Harrison
BRD | Director/Board Member | 63 | 01/17/01 |
Jane Henderson
BRD | Director/Board Member | 59 | 23/19/23 |
Mark Iwicki
CHM | Chairman | 57 | 01/18/01 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.18% | 0 M€ | 0.00% | - | |
0.12% | 237 M€ | +2.89% | - | |
0.10% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
26/24/26 | 19.74 | +4.28% | 753,132 |
25/24/25 | 18.93 | -6.56% | 828,667 |
24/24/24 | 20.26 | -3.52% | 627,391 |
23/24/23 | 21 | +1.01% | 556,045 |
22/24/22 | 20.79 | +0.14% | 711,336 |
Delayed Quote Nasdaq, April 27, 2024 at 01:30 am IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-15.46% | 1.37B | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- AKRO Stock